Organic Active Ingredients TRIZ Cases

A modified oligonucleotide reduces kallikrein mRNA and protein levels through complementary base pairing.

Ester-linked histone deacetylase inhibitors degrade into inactive fragments upon systemic absorption.

A sodium deoxycholate aqueous formulation maintains a pH of 8.0 to 8.5 to inhibit precipitation and stabilize the active ingredient concentration.

A portable transdermal patch uses iontophoresis to drive drug absorption through the skin barrier.

A pharmaceutical composition of orlistat and acarbose reduces caloric uptake from the jejunum to manage body weight.

Incorporating short chain alcohols into luliconazole crystals improves solubility while preventing thermal isomerization during heating steps.

Dispersing nilotinib granules in applesauce creates a swallowable suspension that maintains bioequivalence to intact capsules.

Pyridazinyl amino derivatives inhibit ALK5 via inhalation to treat pulmonary fibrosis while reducing systemic exposure.

Screening compounds by measuring SMN complex relocalization resolves the therapeutic index trade-off against dose-limiting secondary effects.

Expressing enhancing factor proteins Sz-TE2 and Sz-TE3 restores native DHA:DPAn-6 ratios while increasing polyunsaturated fatty acid accumulation levels.

Amphipathic WRAP peptides self-assemble with siRNA cargo to form nanoparticles, resolving cytotoxicity and stability trade-offs in gene silencing.

Optimized pyrimidine structures block Syk kinase to resolve clinical efficacy gaps in treating autoimmune disorders.

Compounds targeting the CNKSR1 pleckstrin homology domain disrupt mutant KRAS signaling, overcoming resistance from diverse amino acid substitutions.

Indole derivatives inhibit efflux pumps, restoring antibiotic efficacy against resistant strains by lowering minimum inhibitory concentrations.

Substituted triazole derivatives modulate gamma-secretase to lower amyloid-beta while improving metabolic stability and central brain availability.

Low-viscosity alginate films bypass gastric degradation and first-pass metabolism by dissolving quickly on mucosal surfaces for rapid systemic absorption.

Mass spectrometry quantifies xanthosine monophosphate in blood to predict drug sensitivity and effective dosing.

Isoquinolinone derivatives target the NK3 receptor to treat psychosis while avoiding extra-pyramidal side effects associated with dopamine D2 blockade.

Phosphoramidate prodrugs bypass inefficient phosphorylation to increase cellular penetration and extend half-life.

Synthetic pseudoceramide mimics natural ceramides to restore epidermal integrity and enhance moisture retention in topical formulations.

Humanized anti-CEACAM5 antibody conjugated with FOLFOX targets tumor cells specifically.

Tropinol esters promote non-amyloidogenic processing of amyloid precursor protein by inhibiting C-terminal cleavage.

Ginsenoside M1 blocks silica crystal-triggered NLRP3 inflammasome activation, reducing IL-1β levels and mitigating lung inflammation caused by silicosis.

Selective HDAC1 and HDAC2 inhibitors reduce off-target side effects while maintaining potent enzyme inhibition efficacy.

Formula I compounds block galectin-3 to treat fibrotic, inflammatory, and cardiovascular diseases.

Local quality tailors DFMO and sulindac administration to ODC1 genotypes, preventing adenomas while avoiding ototoxicity in non-responders.

Transitioning the amorphous compound to Form D resolves production scalability issues while maintaining high purity for pharmaceutical formulations.

Sequencing immunoglobulin genes to design therapeutic agents that specifically target pathological antibodies.

Novel diazaspiro compounds selectively inhibit Rho kinase to overcome drug resistance in cardiovascular treatment.

Trans-capsular injection of p38 MAP kinase inhibitors blocks pro-inflammatory cytokines to reduce pain and inhibit cartilage degradation in facet joints.

Topical celastrol derivatives induce apoptosis in skin cells, treating actinic keratosis without irreversible marks.

Segmented enteric coating releases cholestyramine in the colon, reducing small intestine side effects.

Phosphorodithioate linkages in GNA dimers stabilize double-stranded RNA, reducing off-target toxicity while maintaining interference efficiency.

Gold I gefitinib derivatives overcome drug resistance by simultaneously inhibiting EGFR and TrxR, inducing oxidative stress.

CRISPR-mediated deletion of the BCL11A enhancer reactivates gamma-globin genes, addressing safety risks associated with in vivo gene therapy approaches.

A preservative-free ophthalmic formulation uses solubilizing agents to maintain drug stability and sterility.

Formula I compounds inhibit semicarbazide-sensitive amine oxidase activity through specific aromatic ring linkages and substituents.

Antibodies bind specific polypeptides to identify and treat cancer cells, reducing chemotherapy side effects.

Acellular extracellular matrix combined with platelet-rich plasma stimulates progenitor cells to promote hair growth.

A skin treatment composition uses ceramides, cholesterol, and fatty acids to maintain liquid stability at room temperature.

Formula I compounds block FLT3 and IRAK4 pathways to prevent resistant mutations in acute myeloid leukemia treatment.

Compounds targeting Ral GTPases bypass Ras limitations by trapping inactive conformations to block metastasis.

Photo-crosslinked hyaluronic acid hydrogels sustain house dust mite antigen release, eliminating frequent injections and anaphylaxis risks.

Compounds stabilize mutant CFTR proteins to correct folding defects and restore trafficking efficiency.

Secondary plant metabolites reduce urinary nitrogen concentration, lowering nitrate leaching into groundwater without chemical inhibitors.

Pritelivir hemihydrate combined with polyethylene glycol and artificial tears creates a stable ophthalmic formulation.

A brimonidine and nonionic surfactant composition improves night vision by constricting the pupil to filter optical aberrations.

Segmented phosphorus derivatives with variable substituents inhibit kinase growth and metastasis in resistant cancer cases.

Polymorphic Trandolaprilat prevents diketopiperazine cyclization, maintaining high yield and purity.

Dextrin agent ingested with alcohol lowers blood alcohol concentration levels.

Mucoadhesive polymers in vaginal estriol formulations restrict systemic absorption, preventing estrogen-dependent tumor stimulation.

Human milk oligosaccharides serve as an intermediary substance that reduces gastrointestinal symptoms while restoring intestinal microbiota composition.

Replacing LiAlH4 and thiophosgene with N-bromosuccinimide and thiocyanate salts reduces costs and safety hazards while improving yield.

A nicotine pharmaceutical composition uses a non-hygroscopic sugar substitute to form a glassy matrix for oral delivery.

Nicotinamide di-nucleotide derivatives target visceral pain pathways via TRPV-1 and opioid receptors, reducing morbidity from broad-spectrum analgesics.

Substituted pyrimidinyl-pyrrole compounds inhibit Janus kinases by optimizing substituent patterns to resolve selectivity and potency trade-offs.

N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides inhibit serum and glucocorticoid regulated kinase 1 activity with high plasma stability.

Segmenting fibronectin into specific domains isolates growth factor binding sites, reducing screening complexity while maintaining high specificity.

Pyrimidinedione compounds inhibit CD73 to reduce adenosine, overcoming insufficient therapeutic benefits in combination therapy.

Morpholinyl pyrimidine derivatives inhibit PI3K while resolving stability and safety trade-offs.

Stable riluzole prodrugs bypass rapid hepatic first-pass metabolism, maintaining consistent therapeutic levels in systemic circulation.

Incorporating diflucortolone valerate into the adhesive layer mitigates skin irritation from oxybutynin without causing atrophy.

Formula I compounds inhibit galectin-3 to reduce fibrosis progression by modulating inflammatory pathways.

A (+)-α-dihydrotetrabenazine succinate salt formulation with improved solubility and thermal stability.

A palladium-alumina catalyst enables selective hydrogenation of piperidine derivatives for high-purity pharmaceutical synthesis.

Segmented antibody linkers and local PEG coatings control nanotube integration location while reducing nonspecific interactions.

A fixed-ratio rutin and rapamycin compound inhibits SASP factors to reverse chemotherapy resistance.

Adding n-heptane to a dichloromethane solution of crude Cabazitaxel precipitates high-purity Form-1, avoiding complex solvate preparation steps.

Formula I compounds antagonize the mineralocorticoid receptor, addressing suboptimal hypertension treatments and expanding therapeutic options.

Liposomal irinotecan encapsulates the drug to prolong SN-38 exposure, improving overall survival while reducing neutropenia and diarrhea.

Inhibiting peroxiredoxin 2 disrupts the tankyrase interaction, increasing beta-catenin degradation to reduce colorectal polyp formation.

Polyamine scaffold compounds inhibit bacterial topoisomerase I, bypassing cross-resistance mechanisms in multi-drug resistant tuberculosis.

Injectable composition combining high molecular weight hyaluronic acid with cell culture conditioned medium to treat joint inflammation.

Formula II KSP inhibitors overcome P-glycoprotein efflux resistance by modifying chemical polarity to maintain efficacy against drug-resistant tumors.

A tryptophan-enriched lysozyme hydrolysate composition generates rapid plasma tryptophan elevation through specific peptide fractions.

Neurofilament light chain levels detect transthyretin amyloidosis progression.

Specific polyphenolic compounds increase brain vasculature blood flow, resolving inadequate executive function enhancement in complex tasks.

Formula I compound administered transdermally reduces auditory hyperactivity, addressing neurological dysregulation in moderate to severe tinnitus cases.

Biocompatible polymer composition controls bone bleeding through adhesive paste application without prior preparation.

A dual release oral dosage system combines immediate and delayed components of doxylamine and pyridoxine to modulate active ingredient release timing.

D-amino acid peptide shuttles overcome protease degradation in blood to deliver cargo across the blood-brain barrier.

Toluene-based liquid-liquid separation removes basic impurities from crude efinaconazole through precise aqueous layer pH adjustment.

Non-aqueous solvent suspension stabilizes acid-sensitive proteins within oxidized regenerated cellulose aggregates to prevent denaturation.

Pyrimidine-2-amine compounds inhibit JAK kinases via local quality design, resolving selectivity challenges in treating autoimmune diseases.

Controlled granule properties balance tablet hardness against rapid water disintegration, resolving the firmness trade-off.

Cyanobacterial biomass reduces hepatitis B surface antigen levels, mitigating liver disease risks and insomnia associated with chronic viral infection.

Developing multiple salt forms of COMPOUND I balances improved therapeutic efficacy against increased manufacturing complexity.

A flowable mixture of microencapsulated thyme oil and saponin powder enhances poultry feed conversion efficiency.

MicroRNA-19b suppresses TGFβ signaling to reverse hepatic stellate cell activation and reduce collagen production for fibrosis treatment.

Specific compounds bind Rac-specific GEFs to block cancer cell proliferation while reducing toxicity to normal cells in leukemia treatment.

Pyrazolopyrimidine compounds inhibit JAK1 and JAK2 kinases, achieving sustained lung retention while limiting systemic exposure.